icon-folder.gif   Conference Reports for NATAP  
 
  XVI International AIDS Conference
Toronto Canada
August 13 - 18, 2006
Back grey_arrow_rt.gif
 
 
 
Phase 2 Efficacy and Safety of the Novel Viral Entry Inhibitor, TNX-355, in Combination with Optimized Background Regimen (OBR)
 
 
  Reported by Jules Levin
XVI Intl AIDS Conference, Toronto, Aug 17, 2006
 
D. NORRIS1, J. MORALES2, J. GATHE3, E. GODOFSKY4, F. GARCIA5, R. HARDWICKE6, S. LEWIS7
Comprehensive Research Center, Tampa, FL1, Clinical Research Puerto Rico Inc., San Juan, PR2, Therapeutic Concepts, Houston, TX3, Bach & Godofsky, Bradenton, FL4; Valley AIDS Council, Harlingen, TX5, University of Texas Health Science Center, Houston, TX6, Tanox, Inc., Houston, TX7
 

TNXOveriew-1.gif

MechAction-2.gif

baseline-3.gif

48Week-4.gif

Response-5.gif

grade-6.gif